Summary
Chromatographic analysis of 3′,5′-cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the cytosol of human neutrophils shows the predominant presence of PDE IV (cAMP specific) and PDE V (cGMP specific). PDE IV is characterized by (1) cAMP selectivity, (2) a KM for cAMP of 1.2 M and (3) a typical rank order of IC 50-values for PDE inhibitors: 0.13, 0.17, 47 and 9.5 μM for PDE IV selective rolipram, PDE III/IV selective zardaverine, PDE III selective motapizone and unselective 3-isobutyl-l-methylxanthine (IBMX), respectively. Functions of polymorphonuclear leukocytes (PMN) such as N-formylmethionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide release and fMLP/thimerosal elicited leukotriene (LT) biosynthesis are inhibited by these PDE inhibitors with the same rank order and even lower IC50-values. Measurements of changes in cytosolic Cai in Fura-2 loaded PMN demonstrate a transient Cai increase after stimulation with 0.1 μM fMLP and an additional sustained elevation of Cai levels in the presence of thimerosal. PDE inhibitors suppress this sustained phase of Cai release with the same rank order of IC50-values as LT biosynthesis. The correlation between fMLP/thimerosal-induced LT biosynthesis and Cai levels reveal a Cai threshold of 150 nM for arachidonic acid metabolism. cAMP levels in PMN were elevated by PDE inhibitors alone by less than 2-fold. In the presence of fMLP however, cAMP was increased up to 10-fold and the efficacy of PDE inhibitors to increase cAMP paralleled their potency to inhibit PDE IV. It is concluded that (1) suppression of PMN functions is achieved by PDE IV inhibition, (2) necessary cAMP elevations are within 50% increase, (3) superoxide release was affected by cAMP/protein kinase A (PKA) directly whereas (4) for inhibition of LT biosynthesis a cAMP related reduction of Ca-influx is involved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Appleman MM, Ariano MA, Takemoto DJ, Whitson RH (1982) Cyclic nucleotide phosphodiesterases. In: Nathanson JA, Kebabian JW (eds) Handbook of experimental pharmacology, vol 58/1. Springer, Berlin Heidelberg New York, pp 262–300
Barsony J, Marx SJ (1990) Immunocytology on microwave-fixed cells reveals rapid and agonist-specific changes in subcellular accumulation patterns for cAMP or cGMP. Proc Natl Acad Sci USA 87:1188–1192
Bauer AC, Schwabe U (1980) An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-sephadex columns. Naunyn-Scbmiedeberg's Arch Pharmacol 311:193–198
Beavo JA, Reifsnyder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150–155
Bryson SE, Rodger IW (1987) Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolation airway smooth muscle. Br J Pharmacol 92:673–681
Dent G, Evans PM, Chung KF, Barnes PJ (1990) Zardaverine inhibits respiratory burst activity in human eosinophils. Am Rev Resp Dis 141: A392
Dent G, Rabe K, Giembycz MA, Barnes PJ (1990a) Inhibition of eosinophil respiratory burst activity by type IV-, but not by type III cAMP phosphodiesterase inhibitors. Am Rev Resp Dis 141:A878
Engerson T, Legendre J, Jones HP (1986) Calmodulin-dependency of human neutrophil phosphodiesterase. Inflammation 10:31–35
Galvan M, Schudt C (1990) Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle. NaunynSchmiedeberg's Arch Pharmacol 342:221–227
Giembycz MA, Rabe K, Dent G, Barnes P (1991) Identification and partial characterisation of cyclic nucleotide-dependent phosphodiesterase activities in guinea-pig peritoneal eosinophils. Br J Pharmacol 102:29P
Grady PG, Thomas LL (1986) Characterization of cyclic-nucleotide phosphodiesterase activities in resting and N-formylmethionyl-leucylphenylalanine-stimulated human neutrophils. Biochem Biophys Acta 885:282–293
Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440–3450
Haines KA, Giedd KN, Rich AM, Korchak HM, Weissmann G (1987) The leukotriene B4 paradox: neutrophils can, but will not, respond to ligand-receptor interactions by forming leukotriene B4 or its ω-metabolites. Biochem J 241:55–62
Harris AL, Connell MJ, Ferguson EW, Wallace AM, Gordon RJ, Pagani ED, Silver PJ (1989) Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 251:199
Hatzelmann A, Ullrich V (1987) Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem 169:175–184
Hatzelmann A, Haurand M, Ullrich V (1990) Involvement of calcium in the thimerosal-stimulated formation of leukotriene by fMLP in human polymorphonuclear leukocytes. Biochem Pharmacol 39:559–567
Iannone M, Wolberg G, Zimmerman TP (1989) Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine. J Biol Chem 264:20177–20180
Kammer GM (1988) The adenylate cyclase-CAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9:222–229
Kilian U, Beume R, Eltze M, Schudt Ch (1989) Is phosphodiesterase inhibition a relevant bronchospasmolytic principle? Agents Act Suppl 28:331–348
Kincaid RL, Stith-Coleman IE, Vaughan M (1985) Proteolytic activation of calmodulin-dependent cyclic nucleotide phosphodiesterase. J Biol Chem 260:9009–9015
Kleine-Tebbe J, Wicht L, Friese A, Schunack W, Schudt C, Kunkel G (1989) Inhibition of IgE-mediated histamine release from basophiles by selective phosphodiesterase inhibitors. Allergology 12[Suppl]:12
Kuehl FA Jr, Zanetti ME, Soderman DD, Miller DK, Ham EA (1987) Cyclic AMP-dependent regulation of lipid mediators in white cells. Am Rev Respir Dis 136:201–213
Lad PM, Goldberg BJ, Smiley PA, Olson CV (1985) Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils. Biochem Biophys Acta 846:286–295
Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S (1987) Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochem Pharmacol 36:13–20
di Marzo V, Tippins JR, Morris HR (1989) The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides. Eur J Pharmacol 162:115–121
Murray KJ, England PJ, Reeves ML (1987) Positive isotropic actions of SK & F 94120 occur via a cyclic AMP-dependent mechanism: Action of CAMP-protein kinase. Br J Pharmacol 92:755P
Murray KJ, England PJ, Hallam TJ, Maguire J, Moores K, Reeves M, Simpson AWM, Rink TJ (1990) The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br J Pharmacol 99:612–616
Nicholson CD, Challiss RAJ, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19–27
Nielson CP, Vestal RE, Sturm RJ, Heaslip R (1990) Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86:801–808
Nourshargh S, Hoult JRS (1986) Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors. Eur J Pharmacol 122:205–212
Reeves ML, Leigh BK, England PJ (1987) The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J 241:535–541
Schatz-Munding M, Hatzelmann A, Ullrich V (1991) The involvement of extracellular calcium in the formation of 5-lipoxygenase metabolites by human polymorphonuclear leukocytes. Eur J Biochem 197:487–493
Schudt C, Näher M, Müller B (1989) The effect of phosphodiesterase inhibitors on platelet aggregation and on O2 − release from neutrophils is mediated by different PDE isoenzymes. Allergology 12[Suppl]:12
Schudt C, Winder S, Eltze M, Kilian U, Beume R (1991) Zardaverine: A cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl 34:379–402
Schudt C, Winder S, Müller B, Ukena D (1991a) Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol 42153–162
Silver PL, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB (1988) Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol 150:85–94
Simchowitz L, Spilberg I, Atkinson JP (1983) Evidence that the functional responses of human neutrophils occur independently of transient elevations in cyclic AMP levels. J Cyclic Nucleotide Protein Phosphorylation Res 9:35–47
Smolen JE, Korchak HM, Weissmann G (1980) Increased levels of cyclic adenosine-3′,5-′-monophosphate in human polymorphonuclear leukocytes after surface stimulation. J Clin Invest 65:1077–1085
Takenawa T, Ishitoya J, Nagai Y (1986) Inhibitory effect of prostaglandin E2, forskolin and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils. J Biol Chem 261:1092–1098
Verghese MW, Fox K, McPhail LC, Snyderman R (1985) Chemoattractant-elicited alterations of CAMP levels in human polymorphonuclear leukocytes require a Ca2+-dependent mechanism which is independent of transmembrane activation of adenylate cyclase. J Biol Chem 260:6769–6775
Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 35:787–800
Author information
Authors and Affiliations
Additional information
Send offprint requests to Ch. Schudt at the above address
Rights and permissions
About this article
Cite this article
Schudt, C., Winder, S., Forderkunz, S. et al. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai . Naunyn-Schmiedeberg's Arch Pharmacol 344, 682–690 (1991). https://doi.org/10.1007/BF00174752
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00174752